Tim Anderson
Stock Analyst at B of A Securities
(3.47)
# 2,122
Out of 5,182 analysts
51
Total ratings
51.72%
Success rate
6.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $68 → $67 | $58.26 | +15.00% | 3 | Apr 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $227.79 | -2.98% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $874.00 | +45.08% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $110.03 | +9.06% | 5 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $731.77 | -14.32% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.48 | +13.29% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $339.57 | -19.90% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $85.37 | +1.91% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $5.59 | +347.23% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $197.69 | +3.19% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $129.26 | -2.52% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $47.14 | -27.87% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $183.38 | -2.93% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $145.50 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $186.68 | - | 1 | Sep 22, 2017 |
Bristol-Myers Squibb Company
Apr 9, 2026
Maintains: Buy
Price Target: $68 → $67
Current: $58.26
Upside: +15.00%
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $227.79
Upside: -2.98%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $874.00
Upside: +45.08%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $110.03
Upside: +9.06%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $731.77
Upside: -14.32%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.48
Upside: +13.29%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $339.57
Upside: -19.90%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $85.37
Upside: +1.91%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $5.59
Upside: +347.23%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $197.69
Upside: +3.19%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $129.26
Upside: -2.52%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $47.14
Upside: -27.87%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $183.38
Upside: -2.93%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $145.50
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $186.68
Upside: -